Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.14T
Market cap1.14T
Price-Earnings ratio
40.59
Price-Earnings ratio40.59
Dividend yield
0.57%
Dividend yield0.57%
Average volume
2.95M
Average volume2.95M
High today
$1,208.18
High today$1,208.18
Low today
$1,122.22
Low today$1,122.22
Open price
$1,130.86
Open price$1,130.86
Volume
3.69M
Volume3.69M
52 Week high
$1,208.18
52 Week high$1,208.18
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 1.14T, Eli Lilly(LLY) trades at $1,206.33. The stock has a price-to-earnings ratio of 40.59 and currently yields dividends of 0.57%.

On 2026-06-26, Eli Lilly(LLY) stock moved within a range of $1,122.22 to $1,208.18. With shares now at $1,206.33, the stock is trading +7.5% above its intraday low and -0.2% below the session's peak.

Trading activity shows a volume of 3.69M, compared to an average daily volume of 2.95M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,208.18 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,208.18 and a low of $623.78.

LLY News

TipRanks 2h
Eli Lilly Expands Donanemab Alzheimer’s Trial Into China, Targeting Preclinical Patients

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium...

TipRanks 2h
Lilly Ends Early-Stage Prostate Cancer Combo Trial, Nudging Investor Focus Back to Core Oncology Assets

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium...

TipRanks 3h
Here’s Why Eli Lilly Stock Is Up 6% Today

Eli Lilly’s (LLY) stock is up 6% on June 26 after European regulators backed the company’s new cancer drug called Jaypirca (Pirtobrutinib). Unlock powerful inv...

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

Nasdaq 6h
Lilly's Jaypirca Receives Positive CHMP Opinion For EU Approval In Chronic Lymphocytic Leukemia

(RTTNews) - Eli Lilly and Co. (LLY, LLY.DE) on Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, is...

Lilly's Jaypirca Receives Positive CHMP Opinion For EU Approval In Chronic Lymphocytic Leukemia
Nasdaq 6h
Fidelity vs. iShares: Which Healthcare ETF Delivers Better Value?

Key Points iShares Global Healthcare ETF provides exposure to international markets, while Fidelity MSCI Health Care Index ETF focuses exclusively on U.S.-base...

Fidelity vs. iShares: Which Healthcare ETF Delivers Better Value?
TipRanks 7h
Eli Lilly’s Jaypirca recommended by CHMP for approval in EU

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for Jayp...

TipRanks 1d
Lilly Targets Youth Diabetes With New Oral GLP-1 Trial, Expanding Its GLP-1 Footprint

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium...

Nasdaq 1d
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

Key Points "The field is getting more crowded -- but Lilly is widening its lead,” said RBC analyst Trung Huynh. Until Novo Nordisk gets back to positive growt...

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
Seeking Alpha 1d
ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly

ProQR Therapeutics (PRQR) has priced a registered direct offering of 27.6M ordinary shares at $1.81 per share, expecting to raise about $50M in gross proceeds b...

ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly
TipRanks 1d
Eli Lilly price target raised to $1,232 from $1,119 at Leerink

Leerink analyst David Risinger raised the firm’s price target on Eli Lilly (LLY) to $1,232 from $1,119 and keeps an Outperform rating on the shares. Unlock pow...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.